Lv21
160 积分 2024-03-05 加入
Gastrointestinal and hepatobiliary toxicities associated with bispecific antibody therapy in hematologic malignancies: A retrospective single-center study
2小时前
待确认
Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology
1个月前
已完结
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
1个月前
已完结
Epcoritamab: First Approval
3个月前
已完结
Characterizing “Adversity” of Pathology Findings in Nonclinical Toxicity Studies
3个月前
已完结
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
5个月前
已完结
RNA Interference With Zilebesiran for Mild to Moderate Hypertension
6个月前
已完结
Key considerations in the preclinical development of biosimilars
7个月前
已完结
Considerations for Assessment of Reproductive and Developmental Toxicity of Oligonucleotide-Based Therapeutics
7个月前
已完结
皖公网安备34019202002308
